Journal article
norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis
- Abstract:
-
Background & Aim Primary sclerosing cholangitis (PSC) represents a devastating bile duct disease, currently lacking effective medical therapy. 24-norursodeoxycholic acid (norUDCA) is a side chain-shortened C23 homologue of UDCA and has shown potent anti-cholestatic, anti-inflammatory and anti-fibrotic properties in a preclinical PSC mouse model. A randomized controlled trial, including 38 centers from 12 European countries, evaluated the safety and efficacy of three doses... Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Version of record, pdf, 193.8KB)
-
(Version of record, pdf, 16.1MB)
-
(Version of record, pdf, 323.1KB)
-
(Version of record, pdf, 984.9KB)
-
- Publisher copy:
- 10.1016/j.jhep.2017.05.009
Authors
Bibliographic Details
- Publisher:
- Elsevier Publisher's website
- Journal:
- Journal of Hepatology Journal website
- Volume:
- 67
- Issue:
- 3
- Pages:
- 549-558
- Publication date:
- 2017-05-18
- Acceptance date:
- 2017-05-06
- DOI:
- EISSN:
-
1600-0641
- ISSN:
-
0168-8278
- Pmid:
-
28529147
- Source identifiers:
-
900890
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
pubs:900890
- UUID:
-
uuid:8a82ad46-7070-46f2-bf70-23d149e84a68
- Local pid:
- pubs:900890
- Deposit date:
- 2019-01-30
Terms of use
- Copyright holder:
- European Association for the Study of the Liver
- Copyright date:
- 2017
- Notes:
- Copyright © 2017 European Association for the Study of the Liver. Published by Elsevier B.V. Under a Creative Commons license.
If you are the owner of this record, you can report an update to it here: Report update to this record